The following charts describe the shareholder structure of Fresenius SE & Co. KGaA (as of June 30, 2026). The Else Kröner-Fresenius-Stiftung is the largest shareholder of Fresenius SE & Co. KGaA, with 27% of the shares. In addition, we received several notifications pursuant to the German Securities Trading Act (WpHG) as listed below.
Shareholder structure by investors
.
Shareholder structure institutional investors by region
Full text of the publications in accordance with Section 40 German Securities Trading Act (WpHG) (until January 2, 2018, in accordance with Section 26 WpHG) :
Related Links
Interactive ToolHere you will find the key figures for the Fresenius Group. Additional key financial figures are available at our interactive analysis tool, which can be used to process or analyze the figures in graphical form.
Key Credit Figures Fresenius Group (IFRS)
| 2024 | 2023 | 2022 | |
|---|---|---|---|
Net debt/EBITDA1,2,3 | 3.0 | 3.8 | 3.8 |
| |||
Debt (€m)1 | 13,577 | 15,830 | 14,708 |
Net debt (€m)1 | 11,295 | 13,268 | 13,316 |
| |||
Cash Conversion Rate1 | 1.0 | 1.0 | 0.9 |
EBITDA/Financial result1,3 | 8.3 | 8.4 | 13.8 |
-
1 The previous year’s figures were adjusted due to divestments and the deconsolidation of Fresenius Medical Care
2 Proforma closed acquisitions/divestitures, including lease liabilities, including Fresenius Medical Care dividend
3 Before special items
The Fresenius SE & Co. KGaA Commercial Paper Program enables Fresenius to issue short-term notes of up to €1.5 bn on the money market. The issuances are made through the European Commercial Paper Program (ECP).
Commercial Paper Program
| Issuer | Fresenius SE & Co. KGaA, Fresenius Finance Ireland plc. |
|---|---|
Program amount | € 1,500,000,000 |
Arranger | Commerzbank |
Dealer | Barclays, Commerzbank, Crédit Agricole, DZ BANK AG, Landesbank Baden-Württemberg, Landesbank Hessen-Thüringen, ING Bank N.V. |
Issuing and paying agent | Commerzbank |
Term | up to 1 year less 1 day |
Fresenius Kabi is investing about €35 million to modernize the company’s production facility in Louviers, France. Two sterilization units and two production lines for Freeflex® infusion bags will be housed in a 3,300-square-meter (35,500-square-foot) building being constructed on the site and will replace the existing production facilities. In this way, the company will continue to ensure the availability of these important products into the future. The modernization is scheduled for completion before the end of 2023. Fresenius Kabi employs some 370 people at the Louviers plant and has a total of about 1,500 employees in France.
Fresenius Kabi is investing about €35 million to modernize the company’s production facility in Louviers, France. Two sterilization units and two production lines for Freeflex® infusion bags will be housed in a 3,300-square-meter (35,500-square-foot) building being constructed on the site and will replace the existing production facilities. In this way, the company will continue to ensure the availability of these important products into the future. The modernization is scheduled for completion before the end of 2023. Fresenius Kabi employs some 370 people at the Louviers plant and has a total of about 1,500 employees in France.
With our interactive tool you can analyze and graph a variety of key figures of the Fresenius Group and the business segments on an annual and quarterly basis.
Financial key figures
More information
Sustainability
More informationContact
Vice President Investor Relations
Deputy Head of Investor Relations
T: +49 (0) 6172 608-5167
florian.feick@fresenius.com
Download
Related Links
Alternative Performance MeasuresIn this year's ranking, the non-profit organization CDP has confirmed Fresenius' classification in the second-highest category B. Fresenius is thus once again one of the leading companies in the health care sector. Companies in categories A and B are characterized by transparency, coordinated climate protection measures and the implementation of corresponding best-practice approaches. CDP is one of the most renowned climate and environmental rankings in the capital market. More than 590 investors use the annual results to evaluate climate protection activities and climate-related risks and opportunities of the companies assessed.
In this year's ranking, the non-profit organization CDP has confirmed Fresenius' classification in the second-highest category B. Fresenius is thus once again one of the leading companies in the health care sector. Companies in categories A and B are characterized by transparency, coordinated climate protection measures and the implementation of corresponding best-practice approaches. CDP is one of the most renowned climate and environmental rankings in the capital market. More than 590 investors use the annual results to evaluate climate protection activities and climate-related risks and opportunities of the companies assessed.
In this year's ranking, the non-profit organization CDP has confirmed Fresenius Medical Care' classification. The company was again listed in the second highest categories B in the area climate and B- in the area water. Fresenius Medical Care is thus once again one of the leading companies in the health care sector. Companies in categories A and B are characterized by transparency, coordinated climate protection measures and the implementation of corresponding best-practice approaches. CDP is one of the most renowned climate and environmental rankings in the capital market. More than 590 investors use the annual results to evaluate climate protection activities and climate-related risks and opportunities of the companies assessed.